Document Detail


Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
MedLine Citation:
PMID:  24438614     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: The preclinical experiments and several clinical studies showed icotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in Chinese patients with advanced non-small cell lung cancer (NSCLC) who failed previous chemotherapy. We performed a retrospective study of the efficacy and safety of icotinib monotherapy in a different and more recent sample of Chinese patients.
METHODS: The clinical data of 149 patients with advanced NSCLC who were admitted to Zhejiang Cancer Hospital from August 1, 2011 to July 31, 2012 were retrospectively analyzed. All patients were given icotinib treatment after the failure of previous chemotherapy. Univariate and multivariate analyses were conducted based on the Kaplan Meier method and Cox proportional hazards model.
RESULTS: The objective response rate was 33/149 and disease control rate was 105/149. No complete response occurred. Median progression free survival (PFS) with icotinib treatment was 5.03 months (95% CI: 3.51 to 6.55). Median overall survival was 12.3 months (95% CI: 10.68 to 13.92). Multivariate analysis showed that the mutation of EGFR and one regimen of prior chemotherapy were signi?cantly associated with longer PFS. At least one drug related adverse event was observed in 65.8% (98/149) of patients, but mostly grade 1 or 2 and reversible and none grade 4 toxicity.
CONCLUSIONS: Icotinib monotherapy is an effective and well tolerated regimen for Chinese patients with NSCLC after the failure of chemotherapy. It is a promising agent and further study with icotinib in properly conducted trials with larger patient samples and other ethnic groups is warranted.
Authors:
Lan Shao; Beibei Zhang; Chunxiao He; Baochai Lin; Zhengbo Song; Guangyuan Lou; Xinmin Yu; Yiping Zhang
Related Documents :
24674404 - Feasibility and toxicity of hypofractionated image guided radiation therapy for large v...
23525704 - Egfr and ttf-1 gene amplification in surgically resected lung adenocarcinomas: clinicop...
10890774 - Multidimensional assessment of voice characteristics after radiotherapy for early glott...
23429914 - Current status and future strategies for multimodality treatment of unresectable stage ...
6257374 - Progress in the chemotherapy of small cell carcinoma of the lung.
7599284 - The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  127     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-01-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  266-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive...
Next Document:  Validation and target gene screening of hsa-miR-205 in lung squamous cell carcinoma.